PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...

10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.) Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.

10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.) "After a record year of innovation, we continue to push the boundaries of what's possible in single cell and spatial biology, taking on the hardest ...

PLEASANTON, Calif., Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in ...

Global Biospecimen Leader to Unveil Transformative Tool for Oncology Studies HUNTSVILLE, Ala., Feb. 25, 2025 /PRNewswire/ -- ...

Citi lowered the firm’s price target on 10x Genomics (TXG) to $15 from $20 and keeps a Buy rating on the shares. The firm updated models in the ...

Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating restated by equities researchers at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports. A number of ...

Genomics announced that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences.

10x Genomics (TXG) provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, in the United States District Court for the District of ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.